


RealRate

PHARMACEUTICAL 2019

Theriva Biologics Inc. Rank 86 of 363







RealRate

Theriva Biologics Inc. Rank 86 of 363

The relative strengths and weaknesses of Theriva Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Theriva Biologics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 190%, being 153% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	29,511
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,384
Liabilities, Non-Current	0
Other Assets	23
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	302
Other Net Income	4,150
Other Revenues	0
Property and Equipment	607
Research and Development	11,844
Selling, General and Administrative Expense	5,727

Output Variable	Value in 1000 USD
Assets	30,141
Liabilities	3,686
Expenses	17,571
Revenues	0
Stockholders Equity	26,455
Net Income	-13,421
Comprehensive Net Income	-13,421
Economic Capital Ratio	190%

